Biosimilar

In October, Boehringer Ingelheim’s Cyltezo was approved by the FDA as the first interchangeable biosimilar to AbbVie’s Humira.

In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?

The most-read FDA approval stories of 2021 include Tyrvaya nasal spray and Byooviz, the first ophthalmology biosimilar to receive FDA approval.

The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic response in children and adults with type 1 diabetes and adults with type 2 diabetes.

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

As novel treatment options, including biosimilars, for age-related macular degeneration emerge, it has become a “fascinating time to practice,” according to Aleksandra Rachitskaya, MD.

Express Scripts will prefer Viatris’ insulin glargine-yfgn injection, the first FDA-approved interchangeable biosimilar insulin product, on its largest formulary, the company announced in a press release.

The FDA has designated Cyltezo the first approved interchangeable biosimilar to treat certain inflammatory diseases, allowing pharmacists to substitute it for Humira without the need for the prescriber to alter the prescription.

Samsung Bioepis and Biogen’s collaboration on the approval of Byooviz, a biosimilar referencing Lucentis, ushers in a new period of biosimilar anti-VEGF biologics in retina and more choices for both patients and physicians.

The FDA has approved Byooviz as a biosimilar to Lucentis for the treatment of some retinal diseases and conditions, including wet age-related macular degeneration, according to a press release from Samsung Bioepis and Biogen.